Simultaneous use of parenteral magnesium sulfate and intravenous
Calcium salts is also used in patients with post-parathyroidectomy
“hungry bones” syndrome or tetany associated with
Hypocalcemia and hypomagnesemia. Oral calcium-containing
Medications may increase serum calcium or magnesium concentrations
In susceptible patients, primarily patients with renal
Administration of oral magnesium salts with cellulose sodium
Phosphate or edetate disodium (EDTA) may result in binding of
Magnesium. Do not administer oral magnesium salts within 1 hour of
Cellulose sodium phosphate or edetate disodium.
Concurrent use of cardiac glycosides with magnesium salts may
Inhibit absorption and possibly decrease plasma concentrations of
Cardiac glycosides. Because cardiac conduction changes and heart
Block may occur magnesium slats must be administered with extreme
Caution in digitalized patients, especially if intravenous calcium
Salts are also used.
Diuretics may interfere with the kidneys ability to regulate
Magnesium concentrations. Long-term use of loop diuretics or
Thiazide diuretics may impair the magnesium-conserving ability of
The kidneys and lead to hypomagnesemia. Conversely, long-term use
Of potassium-sparing diuretics has been found to increase renal
Tubular reabsorption of magnesium which may cause hypermagnesemia
In patients also receiving magnesium supplements, especially in
Patients with renal insufficiency.
Concurrent use of magnesium supplements with other
Magnesium-containing antacids or laxatives may result in magnesium
Toxicity, especially in patients with renal impairment.
Administration of oral magnesium salts with oral tetracyclines or
Quinolone antibiotics may form nonabsorbable complexes resulting
In decreased absorption of tetracyclines and quinolones. Do not
Administer oral magnesium salts within 1—3 hours of taking an
Oral tetracycline or oral fluoroquinolone.
Oral magnesium salts may prevent absorption of oral etidronate. Do
Not administer magnesium salts within 2 hours of oral etidronate.
Clinically significant drug interactions have occured when IV
Magnesium salts were given concurrently with nifedipine during the
Treatment of hypertension or premature labor during pregnancy. The
Women affected presented with either pronounced muscle weakness
And/or hypotension. In a few cases, fetal harm was noted as a
Result of the hypotensive episodes. The effects have been
Attributed to nifedipine potentiation of the neuromuscular
Blocking effects of magnesium. It is recommended that nifedipine
Not be given concurrently with magnesium therapy for pre-eclampsia,